WO1985000167A1 - Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation - Google Patents

Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation Download PDF

Info

Publication number
WO1985000167A1
WO1985000167A1 PCT/FR1984/000159 FR8400159W WO8500167A1 WO 1985000167 A1 WO1985000167 A1 WO 1985000167A1 FR 8400159 W FR8400159 W FR 8400159W WO 8500167 A1 WO8500167 A1 WO 8500167A1
Authority
WO
WIPO (PCT)
Prior art keywords
radical
alk
cysteamine
compound according
mole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1984/000159
Other languages
English (en)
French (fr)
Inventor
Joël OIRY
Jean-Louis Imbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of WO1985000167A1 publication Critical patent/WO1985000167A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Definitions

  • Radioprotectors represent a class of compounds particularly studied in the literature and characterized, for most of them, by the presence of an SH function or one of its bloprecursors.
  • the main mode of action of these compounds is linked to the capacity presented by the thiol group to trap free radicals induced intracellularly by radiation of various kinds, thus preventing permanent damage in the cells.
  • a typical structure, one of the most studied, is that of cysteamine (or MEA) (1):
  • This compound is substituted on the N-side of the cysteamine by an aminoalkyl chain and on the S-side by a phosphorothioate function which has the double advantage of conferring good aqueous solubility on the molecule and of protecting in the first stage the thiol function which can be released "in situ" by the action of phosphatases or even by hydrolysis.
  • radioprotectors lead to non-selective protection of cells, whether healthy or malignant (for example cysteamine, cysteine, etc.).
  • the WR 2721 has the remarkable property of selectively protecting normal tissues against radiation-induced damage while allowing solid tumors to withstand the effect of radiation alone.
  • this drug concentrates selectively in healthy cells and not in cancer cells. The origin of this selectivity is not yet firmly established.
  • WR 2721 also appears to be able to exert a selective protective effect during chemotherapy with alkylating drugs such as cisplatin, cyclophosphamide and nitrogen mustards.
  • alkylating drugs such as cisplatin, cyclophosphamide and nitrogen mustards.
  • this compound is the first radiation protector approved by the PDA and has been the subject of phase I studies in both the United States of America and Japan.
  • the present invention relates to cysteamine derivatives which have good selective radioprotective power and some of which are interferon inducers.
  • the compounds according to the present invention correspond to the formula:
  • R 1 -CO-S- / A / -NR- 5 -R 2 in which R "is a radical corresponding to an amino acid or a di or tripseudopeptide R 1 -COOH, / A / is iin radical C 2 or C 3 alkylene which may be substituted by one or more C 1 alkyl radicals.
  • R is an amino radical or -NH-CH 2 -CO 2 -H
  • R 2 is a protective radical of the thiol function which releases the thiol function "in vivo”
  • R 3 is hydrogen or a C 1 to C 3 alkylene radical or, linked to the group R 2 , forms a protective ring for the thiol function.
  • the invention also relates to the salts of these compounds with pharmaceutically acceptable acids.
  • R 1 is a straight or branched C 1 -C 7 alkyl-amino radical, in particular C 1 to C 4 such as alanine derivatives , glycine and sarcosine as well as the alkyl derivatives substituted on the amine.
  • the radical R 1 can also come from a di or tripseudopeptide, by "pseudopeptide” on intends to designate a sequence of 2 or 3 natural or unnatural amino acids, such as those defined above, for example a gly-gly or ala-gly sequence.
  • Ro is defined as a protective radical of the thiol function, this is true literally in the case of compounds (la), but for compounds (Ib) which are symmetrical derivatives of (la), this is d 'a functional definition since R 2 is not on a sulfur atom but on an amino function, nevertheless tests have shown that the two types of compounds, (la) and (Ib) had similar properties.
  • R 4 O, S, NH, N (C 1 -C 7 ) alkyl
  • R 5 H, C 1 -C 7 alkyl, substituted or unsubstituted aryl, NH 2 , SH; either by a bioreductive activation of a disulfide bridge, for example:
  • R ' H, C 1 -C 7 -alkyl, aryl, NH 2
  • R " H, C 1 -G 7 -alkyl, aryl.
  • aryl radicals mention should be made of monocyclic aryl radicals, in particular the phenyl radical which may be substituted by one or more halogen atoms, in particular chlorine, by one or more C 1 -C 3 -alkyl or hydroxy radicals.
  • R 7 is H or a C 1 to C 3 alkyl radical
  • alk 1 is a straight or branched C 1 to C 7 alkylene chain
  • alk 2 is an ethylenyl or propylenyl chain carrying one or more free methyl or hydroxy radicals or esterified
  • alk 3 is a C 1 -C 7 -alkyl radical unsubstituted or substituted by one or more chlorine atoms, and in particular: glycyl-N- (S-acetyl) -cysteamine, L-alanyl-N- (S-acetyl) -cysteamine, ⁇ -aminobutyryl-N- (S-acetyl) -cysteamine, glycyl-N- (S-dichloroacetyl) -cysteamine, glycylamino-2-dimethyl-2,2-thioacetyl-1-ethane I 108,
  • R 8 is H or a C 1 to C 3 alkyl radical
  • alk 1 is a straight or branched C 1 to C 7 alkylenyl chain
  • alk 2 is an ethylenyl or propylenyl chain carrying one or more free methyl or hydroxy radicals or esterified, and in particular: diglycyl-N, K'-cystamine, di-L-alanyl-N, N'-cystamine, di- ⁇ -aminobutyryl-N, N'-cystamine, di- (glycylamino- 3-acetoxy-2-propyl) -1.2 disulfide
  • R 7 or R 8 represents the radical of an amino acid or of a dipeptide, in particular when R 7 or R 8 represents or for example alk ⁇ and alk e being straight or branched C 1 to C 7 alkylene radicals, preferably C 1 to C 4 .
  • R 7 or R 8 represents or for example alk ⁇ and alk e being straight or branched C 1 to C 7 alkylene radicals, preferably C 1 to C 4 .
  • R 7 -NH-alk 1 - (C O) -NH-alk 2 -SR 9 in which E 7 , alk 1 and alk 2 have the meanings given above and R 9 is C-NH 2 , -SO 3 H or -PO 3 H 2
  • glycyl- (N-isothiouronium-2-ethyl) amine (glycylamino-2) -ethylthiosulfuric acid, sodium glycylamino-2-S-ethylphosphorothioate.
  • glycyl- (N-isothiouronium-2-ethyl) amine (glycylamino-2) -ethylthiosulfuric acid, sodium glycylamino-2-S-ethylphosphorothioate.
  • the compounds according to the present invention can be prepared by methods analogous to those used in the synthesis of peptides.
  • the compounds are obtained by coupling an AA H-protected by a Z or by a BOC with an S-substituted cysteamine ( ⁇ -mercaptoethylamine-MEA) (scheme 1).
  • the condensing solvents are ethyl acetate or THF.
  • DCC or t-PNC J. Martine z et al., Bull. Soc. Chim. Fr., 1972, 12, 4707) in the presence of TEA are the coupling agents.
  • terminal amines are then deprotected, either by hydrobromic acid in solution in glacial acetic acid at low temperature for the Z, or by trifluoroacetic acid for the BOCs and obtained in the form of hydrobromides or trifluoroacetates.
  • R 7 succinimido
  • cystamine derivatives can be carried out according to two different methods: Method using the preceding MEA derivatives (diagram 3)
  • the two pseudopeptides N-protected by a Z or a BOC and S-substituted are hydrolyzed by sodium methylate on the S-terminal side and then oxidized by iodine in aqueous acetic acid to form Di-Z or di-BOC cystamine pseudopeptides.
  • the terminal amines are then deprotected with hydrobromic acid in glacial acetic acid solution or with trifluoroacetic acid in the presence of thioanisole.
  • the pseudo-peptides are obtained in the form of their di-hydrobromides or di-trifluoroacetates.
  • di-Z-AA-cystamine or di-BOC-AA-cystamine is obtained directly.
  • These derivatives are synthesized by condensation in DMF in the presence of TEA, an activated Z-AA or a BOC-AA activated on the terminal acid side with an appropriate ester on cystamine.
  • di-Z or di-BOC-AA-amine cysts are then treated with hydrobromic acid in glacial acetic acid solution or with trifluoroacetic acid and provide their respective amine salts.
  • di-Z or di-BOC-AA-cystamine are also obtained from Z or BOC glycines and cystamine using a coupling agent (t-PNC or DCC).
  • Amine salts can be released and replaced by other ions.
  • the liberation of the salts of the diamino acid-cystamines perr and of increasing the chain on the N-terminal side with other amino acids and of forming tetrapseudopeptides, etc. by conventional couplings. It is also possible to obtain them by the conventional methods already mentioned by coupling Z or BOC di, tripeptides, etc., activated or not by an ester, with cystamine (Diagram 5).
  • the present invention also relates to the application of the compounds according to the present invention as radioprotective agent and pharmaceutical compositions containing them for this type of application or else as an interferon-inducing agent in the treatment of diseases sensitive to interferon .
  • the organic phase is then decanted and washed with 2 x 200 ml of 5% ice-cold aqueous hydrochloric acid and with 2 x 200 ml of water (neutral pH) and then dried over sodium sulfate and evaporated to dryness under vacuum. 5 g of a slightly yellow oil are collected.
  • the product is purified by chromatography on a column of silica gel (eluent: ethyl acetate / petroleum ether 8/2).
  • the expected derivative is collected with a yield of 90% in the form of a colorless and very hygroscopic paste. It will be stored under a nitrogen atmosphere or under vacuum.
  • Reagents used 11.25 g (0.005 mole) of Z-alanine in 200 ml of THF. 8.7 g of t-PNC in 20 ml of THF. 7 ml of TEA. 7.75 g (0.005 mole of Sacetyl-c-ysteamine hydrochloride in 150 ml of THF.
  • the mixture is kept basic by adding 7 ml of TEA and the reaction followed by TLC (eluent: dichloromethane / methanol 9/1) is completed in 4 hours After the treatments already described, 15 g of an oil are obtained which is chromatographed on a column of silica gel (eluent: ethyl acetate / petroleum ether 8/2).
  • EXAMPLE 6 BRQMHYDRA.TE OF ⁇ -AMINOBUTYRYL-N- (S-ACETYL) -CYSTEAMINE Prepared according to the general method described above Reagents used: 1.4 g (4.1.10 -3 mole) of Z- ⁇ - aminobutyryl-N- (S-acetyl) -cysteamine. 3 ml HBr / AcOH. After lyophilization in 5 ml of water, 1 g of hygroscopic hydrobromide is collected.
  • reaction mixture is then washed with water and then with saturated aqueous sodium bicarbonate, ice-cold, again with water, then with an ice-cold aqueous solution of 1N citric acid and finally with water until neutral pH.
  • the organic phase is then dried over sodium sulfate and evaporated to dryness under vacuum. 12.5 g of crude oil are collected in the form of an oil.
  • EXAMPLE 8 GLYOYL-N- (S-ACETYL) -CUSTEAMINE TRIFLUOKOACETATE General method for deprotecting a BOC-AA with formation of its corresponding trifluoroacetate Protecting from moisture 2.03 g (7.10 -3 mole) of BOC- glycyl-N- (S-acetyl) -cysteamine are stirred at room temperature with 10 ml of TFA and 0.25 ml of thioanisole. The reaction followed by TLC (eluent: dichloromethane containing 8% methanol) is complete in 4 hours.
  • TLC eluent: dichloromethane containing 8% methanol
  • the trifluoroacéta e is precipitated from the mixture in oily form by the addition of 150 ml of anhydrous ether and washed with 2 x 150 ml of ether then dried in a desiccator under vacuum containing phosphoric anhydride and potassium hydroxide plates . Practically quantitative yield. High purity is obtained by dissolving the salt in 10 ml of distilled water followed by lyophilization.
  • Reagents used 8.69 g (49.10 -3 mole) of BOC-glycine in 160 ml of ethyl acetate. 17.3 g (49.10 -3 mole of t-PNC in 50 ml of ethyl acetate. 7 ml of
  • Reagents used 5.2 g (24.10 -3 mole) of Z-glycine in 50 ml of ethyl acetate. 8.7 g (25.10 -3 mole) of t-PNC in 25 ml of ethyl acetate. 5 ml of TEA. 9.83 g (48.10 -3 -3 mole) bromo-2-ethyl hydrobromide
  • a solution stirred at room temperature of 3.6 g (13.10 -3 mole) of Z-glycyl-N-cysteamine in 15 ml of acetic acid and 15 ml of distilled water is supplemented with 20 ml of acetic acid containing 250 mg of iodine, which causes the immediate formation of a precipitate.
  • the reaction mixture is maintained for 15 minutes at room temperature then the precipitate is filtered, washed with distilled water and then dried in a desiccator under vacuum on phosphoric anhydride. Recrystallizes from a mixture of DMF and distilled water. The crystals formed are drained and then washed with a mixture of ethanol and v / v ether, then with ether.
  • Reagents used 7.2 g (34.10 -3 mole) of Z-gly in 150 ml of ethyl acetate. 12 g (34.10 -3 mole) of t-PNC (DCC can replace t-PNC) in 50 ml of ethyl acetate. 5.1 ml of TEA. 3.04 g (20.10 -3 mole) of cystamine in 30 ml of ethyl acetate.
  • Reagents used 2.252 g (0.01 mole) of cystamine dihydrochloride in 20 ml of DMF and 1.70 ml of TEA. 3.06 g (0.02 mole) of Z-glycyl-O-N-succinimide ester in 30 ml of DMF. The reaction mixture is stirred for 6 hours at room temperature and then evaporated to dryness under vacuum. The remaining paste is triturated in ethyl acetate, which causes the formation of a colorless powder which will be filtered and then washed with distilled water. The remaining product crystallizes under the same conditions as above. After filtration and drying, 3.5 g of a product is collected having physicochemical criteria identical to the previous ones.
  • Reaction made according to the general method already described Reagents used 1.8 g (3.10 -3 mole) of di-Z-diglycyl- N, N'-cystamine. 12 ml glacial acetic acid saturated with hydrobromic acid, gaseous, dry. The mixture is stirred for 4 hours at room temperature, then 100 ml of anhydrous ether are added to it, with vigorous stirring, which promotes the formation of a slightly yellow powder. This powder is drained under vacuum, then washed with 2 x 50 ml of anhydrous ether and crystallized from a mixture of methanol and ether.
  • Reagents used 2.98 g (17.10 -3 mole) of BOC-glycine in 50 ml of ethyl acetate. 5.92 g (17.10 -3 mole) of t-PNC (DCC can replace t-PNC). 2.4 ml of TEA. 2.6 g (17.10 -3 mole) of cystamine in 30 ml of ethyl acetate.
  • Reagents used 5.4 g (24.10 -3 mole) of cystamine dihydrochloride in 50 ml of DMF. 3.4 ml of TEA. 5.44 g (20.10 -3 mole) of BOC-glycyl-ON-succinimide ester.
  • the reaction mixture is stirred for 6 hours at room temperature and treated as above after evaporation to dryness under vacuum and taking up of the paste obtained with 500 ml of ethyl acetate.
  • BOC-glycylthio-2 dimethyl-1, 1 acetamido-1 ethane 1st method, involving the active ester 0-NSu of BOC-glycine and carried out according to the general method: Reagents used: 272 mg (10 -3 mole) of BOC-gly-0NSu, 10 ml of DMF, 280.1 mg (1.23 x 10 -3 mole) thioacetamido-1 methyl-2-amino-2 propane hydrobromide, 0.171 ml of TEA. After the various treatments, the expected derivative is obtained with a yield of 40%. Recrystallizes from a mixture of ethyl acetate and petroleum ether.
  • Reagents used 4.53 g (2.5 g x 10 -2 mole) of BOC-gly, 50 ml of ethyl acetate, 4.51 g (12.9 x 10 -3 mole) of t-PNC, 3.61 ml of TEA, 5.9 g (2.59 x 10 -2 mole) of thioacetamido-1 methyl-2-amino-2 propane hydrobromide,
  • BOC-GLYCYLAMINO-3 BROMO-1 PROPANOL-2 It is obtained according to the general method and it involves the ester O-NSu of glycine N protected as well as the bromohydrate of 1-bromo-3-amino propanol-2 described by DM BALL et al., J. Org. Chem. 1963, 28, 1580.
  • Reagents used 9.21 g (3.38 x 10 -2 mole) of BOC-gly-ONSu, 100 ml of DMF, 7.95 g (3.38 x 10 -2 mole) of bromo-1 amino hydrobromide -3 propanol-2, 4.75 ml (3.38 x 10 -2 mole) of TEA.
  • Reagents used 940 mg (1.5 x 10 -3 moles) of di (BOC-glycylamino-3-acetoxy-2 propyl) -1,2 disulfide; 8 ml of TFA.
  • Reagents used 1.4 g (4 x 10 -3 mole) of BOG-3-glycylamino-2-acetoxy-1-thioacetyl-propane, 6 ml-of TFA.
  • the most polar compound (Rf 0.25) was collected in the form of an oil (2.55 g) which recrystallized from a mixture of ethyl acetate and petroleum ether. M 120 ° C.
  • Reagents used 1.194 g (5.3 x 10 -3 mole) of cystamine dihydrochloride in 40 ⁇ l of DMF and 1.48 ml of TEA. 3.5 g of Boc-glycylglycyl-ON-succinimide ester.
  • the reaction mixture is stirred for 12 hours at room temperature and then evaporated to dryness under vacuum.
  • the remaining dough is taken up in ethyl acetate.
  • the standard washes are then carried out (water, ice-cold saturated aqueous sodium bicarbonate, water, 1% HCl, water until neutral pH).
  • the organic phase is dried over sodium sulfate and then evaporated to dryness under vacuum.
  • Reagents used 9.58 g (50.7 x 10 -3 mole) of BOC-Sarcosine in 70 ml of acetonitrile, 8.82 g (25.3 x 10 -3 mole) of t-PNC in 90 ml d 'acetonitrile. 7.08 ml (50.7 x 10 -3 mole) of TEA. The mixture is stirred at 0 ° C for 15 minutes and added with 8.97 g (57 x 10 -3 mole) of S-acetyl-cysteamine hydrochloride and a solution of 10.86 ml (77 x 10 -3 mole) of TEA. in 30 ml acetonitrile.
  • the reaction mixture is stirred for 12 hours at room temperature and then evaporated to dryness under vacuum.
  • the residue is taken up in 400 ml of dichloromethane and the various washes are carried out (water, ice-cold saturated aqueous sodium bicarbonate, water, citric acid 10% in water, water until neutral pH).
  • the organic phase dried over sodium sulfate and then evaporated to dryness under vacuum, provides 11.9 g of crude product which will be chromatographed on a silica gel column using an eluent consisting of a mixture of ethyl acetate containing 20% ether. of oil. After crystallization, is collected in a mixture of ethyl acetate and petroleum ether 5.52 g of colorless crystals.
  • DI-BOC-SARCOSYL-N, N '-CYSTAMINE Reaction carried out according to the general method already described which involves an activated ester of BOC-Sarcosine and cystamine.
  • Reagents used 3.15 g (14 x 10 -3 mole) of cystamine dihydrochloride in 50 ml of DMF and 3.9 ml of TEA. 7.15 g (25 x 10 -3 mole) of BOC-Sarcosyl-ON-Succinimide ester.
  • DI-SARCOSYL-N N '-CYSTAMINE DI-TRIFLUOROACETATE:
  • Trisodium phosphorothioate is prepared according to the method of S. AKERFELOT; Acta. Chem. Seand., 1960, 14, 1980-84. at the doses indicated in Table I, 15 minutes before irradiation with the LD 100/30 days. This dose being equal to 950 Rad.
  • the derivatives I 107 (example 24) and I 108 (example 28) comprise a glycine for the reasons which have been cited and a cysteamine dimethylated in position ⁇ of the nitrogen atom chosen by analogy with a thio-sulfate described by Piper et al. :
  • the molecule I 109 (example 28) is particularly interesting. It is the first to have a dipeptide sequence on S-acetylated cysteamine. By using a dipeptide (gly-gly) it was desired to reduce the toxicity compared to I 102 while retaining radioprotective activity.
  • the derivative I 114 (example 34), it has an S-glycyl conjugation (see I 107) and can be considered as the reverse of I 102, it has a slight radioprotective action.
  • the anti-carcinogenic activity was determined in mice carrying EMT6 or HT19 tumors. It is injected i.p. 695 mg / kg 15 minutes before the start of irradiation at 20 Gy.
  • WR 2721 One of the best radioprotectors today, WR 2721, is structurally close to I 102 since it contains a cysteamine conjugated with a propylamine group and has its thiol function protected by a phosphorothioate group (unstable, hence the problems encountered to purify WR 2721). In addition, it has been shown, mainly by the work of Yuhas, that WR 2721 has the remarkable property of being selectively concentrated in normal tissues (and not in cancer cells).
  • WR 2721 may exert a selective protective effect during chemotherapy carried out with alkylating drugs.
  • the gain factor (FRD bone marrow / FRD tumors) for a survival level of 5- 10 on ET ⁇ T6 tumors is identical for the two products and equal to 1.2.
  • the I 102 shows two advantages over the WR 2721: - greater chemical stability (the WR 2721 is in fact not very stable, which sometimes leads to non-reproducible results),

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
PCT/FR1984/000159 1983-06-22 1984-06-21 Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation Ceased WO1985000167A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR83/10318 1983-06-22
FR8310318A FR2549051B1 (fr) 1983-06-22 1983-06-22 Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation

Publications (1)

Publication Number Publication Date
WO1985000167A1 true WO1985000167A1 (fr) 1985-01-17

Family

ID=9290052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1984/000159 Ceased WO1985000167A1 (fr) 1983-06-22 1984-06-21 Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation

Country Status (8)

Country Link
US (1) US4816482A (cg-RX-API-DMAC10.html)
EP (1) EP0131500B1 (cg-RX-API-DMAC10.html)
JP (1) JPS60501605A (cg-RX-API-DMAC10.html)
AT (1) ATE27269T1 (cg-RX-API-DMAC10.html)
CA (1) CA1248298A (cg-RX-API-DMAC10.html)
DE (1) DE3463766D1 (cg-RX-API-DMAC10.html)
FR (1) FR2549051B1 (cg-RX-API-DMAC10.html)
WO (1) WO1985000167A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200492A1 (en) * 1985-04-26 1986-11-05 The President And Fellows Of Harvard College Radiodiagnostic agents
US5643966A (en) * 1990-07-06 1997-07-01 University Of New Mexico β-alethine as anti-tumor agent
EP0848011A1 (en) 1996-12-16 1998-06-17 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Method of coupling polysaccharides to proteins
US6245561B1 (en) 1990-07-06 2001-06-12 University Of New Mexico β-alethine use in cell culture and therapy

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2654617B1 (fr) * 1989-11-20 1993-10-08 Oreal Composition cosmetique reductrice pour permanente contenant, en tant qu'agent reducteur, de l'aletheine ou l'un de ses sels, et son utilisation dans un procede de deformation permanente des cheveux.
FR2676441B1 (fr) * 1991-05-17 1994-10-28 Oreal Nouveaux alkylamino-mercaptoalkylamides ou l'un de leurs sels cosmetiquement acceptables, et leur utilisation en tant qu'agents reducteurs, dans un procede de deformation permanente des cheveux.
WO1993016991A1 (es) * 1992-02-28 1993-09-02 Consejo Superior Investigaciones Científicas Tensioactivos cationicos que contienen en su molecula un grupo disulfuro, su procedimiento de obtencion
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
BR0007437A (pt) 1999-01-08 2001-11-20 Procter & Gamble Composições tópicas que compreendem tióisfuncionais protegidos
US6703007B2 (en) * 1999-01-08 2004-03-09 The Procter & Gamble Company Topical compositions comprising functional nucleophiles protected by phosphorus-containing moieties
KR101579095B1 (ko) * 2008-07-16 2015-12-21 엘지전자 주식회사 세탁물 처리기기
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
SG10201800159QA (en) 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
CN115724779B (zh) * 2021-09-01 2024-03-29 四川大学 酰胺烷二硫化合物、其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB710216A (en) * 1952-05-12 1954-06-09 Parke Davis & Co Improvements in or relating to the production of organic disulphides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574996A (en) * 1948-11-18 1951-11-13 Eastman Kodak Co N-(acetylmercaptoacetyl)-n'-n-butylurea

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB710216A (en) * 1952-05-12 1954-06-09 Parke Davis & Co Improvements in or relating to the production of organic disulphides

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200492A1 (en) * 1985-04-26 1986-11-05 The President And Fellows Of Harvard College Radiodiagnostic agents
US5643966A (en) * 1990-07-06 1997-07-01 University Of New Mexico β-alethine as anti-tumor agent
US6046241A (en) * 1990-07-06 2000-04-04 University Of New Mexico β-alethine as anti-tumor agent
US6245561B1 (en) 1990-07-06 2001-06-12 University Of New Mexico β-alethine use in cell culture and therapy
EP0848011A1 (en) 1996-12-16 1998-06-17 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Method of coupling polysaccharides to proteins

Also Published As

Publication number Publication date
EP0131500B1 (fr) 1987-05-20
EP0131500A1 (fr) 1985-01-16
CA1248298A (fr) 1989-01-03
JPS60501605A (ja) 1985-09-26
US4816482A (en) 1989-03-28
JPH0523260B2 (cg-RX-API-DMAC10.html) 1993-04-02
DE3463766D1 (en) 1987-06-25
FR2549051A1 (fr) 1985-01-18
FR2549051B1 (fr) 1986-05-16
ATE27269T1 (de) 1987-06-15

Similar Documents

Publication Publication Date Title
EP0038758B1 (fr) Dérivés d'acides aminés et leur application thérapeutique
EP0131500B1 (fr) Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procédé pour leur préparation
DE3789371T2 (de) Aryloxy- und Arylacyloxymethyl-Ketone als Thiolprotease-Hemmungsstoffe.
US5103018A (en) Mitomycin derivatives
Barlos et al. Efficient" one-pot" synthesis of N-tritylamino acids
EP0082088A1 (fr) Nouveaux dérivés d'aminoacides, et leur application thérapeutique
FR2523132A1 (fr) Inhibiteurs de l'enzyme de transformation de l'angiotensine constitues par des acides phosphiniques substitues par des radicaux aminoalkyle et apparentes
FR2550204A1 (fr) Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
CA2092867A1 (fr) Derives de l-¬2-(arylsulfonylamino)-1-oxoethyl|piperidine, leur preparation et leur application en therapeutique
US5206343A (en) Oligopetides with cyclic proline-analogous amino acids
FR2496654A1 (fr) Nouveaux tri-, tetra- et pentapeptides, leur preparation et les medicaments qui les contiennent
PT87350B (pt) Processo para a preparacao de peptideos com accao de inibicao de fosfolipase a2 e de composicoes farmaceuticas que os contem
KR940007743B1 (ko) 스퍼구알린(Spergualin) 관련 유도체
Oiry et al. Synthesis and radioprotective activity of new cysteamine and cystamine derivatives
SE452318B (sv) Aminosyror till anvendning som mellanprodukter vid framstellning av bestatiner
EP1421065A1 (fr) Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
EP0188947B1 (fr) Peptides réduits, inhibiteurs de la sécrétion gastrique, procédé d'obtention et compositions pharmaceutiques les contenant
HU200985B (en) Process for production of active esthers of carbonic acid
FR2516924A1 (fr) Acides phosphinylalcanoyl- amines a action therapeutique
FR2497800A1 (fr) Nouveaux derives de nitrosouree
FR2564844A1 (fr) Nouveaux peptides derives de la statine, procede d'obtention et compositions pharmaceutiques les contenant
EP1140980B1 (fr) Composes pseudopeptidiques dotes d'une activite inhibitrice a l'egard des voies activees par les proteines a activite tyrosine kinase et les compositions pharmaceutiques les contenant
JPH02209865A (ja) 3―チオプロピオン酸誘導体の製造法
CA2601025C (fr) Nouveaux derives d'aminoacides phosphiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
LU80297A1 (fr) Amides tetrapeptidiques a activite pharmacologique,procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP US

Kind code of ref document: A1

Designated state(s): JP US